Preliminary research suggests that hybrid DCTs can reduce trial timing and resources, improve patient-centricity and patient engagement, and expand access and recruitment and increase diversity, mitigate bias, and reinforce inclusion in clinical trials. A recent Science 37 survey noted that nearly three-quarters (73%) of respondents from the pharma industry were planning a hybrid or DCT, up from 49% in 2021.
“DCTs have been around for many years, long before the pandemic, but now companies have had the opportunity to utilise DCT approaches,” John Reites, CEO of Thread, told pharmaphorum.